Summary
Vertex Pharmaceuticals Inc. reported its second-quarter and first-half 2024 financial results, highlighting continued revenue growth driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO. Despite a significant net loss for the period, largely due to a substantial acquired in-process research and development (AIPR&D) charge related to the acquisition of Alpine Immune Sciences, Inc., the company's core product revenue remains strong. Key developments include the acquisition of Alpine, which significantly impacted the quarter's financials but brought povetacicept into the pipeline for kidney diseases. Vertex is also progressing with its non-CF pipeline, with notable advancements in its sickle cell disease therapy, CASGEVY, and upcoming potential launches for vanzacaftor/tezacaftor/deutivacaftor in CF and suzetrigine for acute pain. The company's liquidity remains robust, although cash reserves have decreased due to the Alpine acquisition.
Financial Highlights
46 data points| Revenue | $2.65B |
| Cost of Revenue | $371.90M |
| Gross Profit | $2.27B |
| SG&A Expenses | $372.20M |
| Operating Expenses | $6.16B |
| Operating Income | -$3.51B |
| Net Income | -$3.59B |
| EPS (Basic) | $-13.92 |
| EPS (Diluted) | $-13.92 |
| Shares Outstanding (Basic) | 258.10M |
| Shares Outstanding (Diluted) | 258.10M |
Key Highlights
- 1Reported net product revenues of $2.65 billion for Q2 2024, a 6% increase year-over-year, driven by strong performance of TRIKAFTA/KAFTRIO. First-half 2024 revenues reached $5.34 billion, up 10%.
- 2Recorded a net loss of $3.59 billion for Q2 2024 ($13.92 per diluted share), compared to a net income of $915.7 million ($3.52 per diluted share) in Q2 2023. The loss was primarily due to a $4.45 billion charge for acquired in-process research and development related to the Alpine acquisition.
- 3Completed the acquisition of Alpine Immune Sciences for approximately $5.0 billion, adding povetacicept, a potential best-in-class treatment for IgA nephropathy, to its pipeline. This acquisition was accounted for as an asset acquisition, resulting in a significant AIPR&D expense.
- 4Continued progress in the development and regulatory filings for key pipeline assets, including vanzacaftor/tezacaftor/deutivacaftor for CF (potential launch Jan 2025) and suzetrigine for acute pain (potential launch Jan 2025).
- 5CASGEVY, for sickle cell disease and beta thalassemia, has received approvals in the U.S., EU, UK, Saudi Arabia, and Bahrain, with ongoing global regulatory submissions and treatment center activations.
- 6Cash, cash equivalents, and marketable securities decreased to $10.2 billion as of June 30, 2024, from $13.7 billion as of December 31, 2023, primarily due to the cash used for the Alpine acquisition.